Augmenta Bioworks and TFF Pharmaceuticals Announce Positive In Vitro Data Demonstrating ...

Retrieved on: 2021-07-29 12:00:00

Tags for this article:

Variants of SARS-CoV-2

Coronaviridae

SARS-CoV-2 Gamma variant

COVID-19

Catalent

SARS-CoV-2 Beta variant

SARS-CoV-2 lineage B.1.617

SARS-CoV-2 Kappa variant

United States

Christopher Emig

Augmenta Bioworks

Click the tags to see associated articles and topics

Augmenta Bioworks and TFF Pharmaceuticals Announce Positive In Vitro Data Demonstrating .... View article details on HISWAI: https://www.globenewswire.com/news-release/2021/07/29/2271201/0/en/Augmenta-Bioworks-and-TFF-Pharmaceuticals-Announce-Positive-In-Vitro-Data-Demonstrating-Binding-and-Neutralization-of-the-SARS-CoV-2-Delta-Variant-by-Lead-Anti-COVID-19-Antibody-AU.html

Excerpt

... that their lead anti-COVID-19 monoclonal antibody (“mAb”) therapy, AUG-3387, binds to and neutralizes the SARS-CoV-2 Delta variant (B.1.617.2).

Article found on: www.globenewswire.com

View Original Article